Innoviva, Inc. (INVA)
Company Description
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally.
The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA.
Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.
The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016.
Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
| Country | United States |
| IPO Date | Oct 5, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 101 |
| CEO | Pavel Raifeld C.F.A. |
Contact Details
Address: 1350 Old Bayshore Highway, Suite 400 Burlingame, California 94010 United States | |
| Phone | (650) 238-9600 |
| Website | inva.com |
Stock Details
| Ticker Symbol | INVA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001080014 |
| CUSIP Number | 45781M101 |
| ISIN Number | US45781M1018 |
| Employer ID | 94-3265960 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Pavel Raifeld C.F.A. | Chief Executive Officer |
| Marianne Zhen CPA | Chief Accounting Officer and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 6, 2023 | 8-K | Current Report |
| Nov 1, 2023 | 10-Q | Quarterly Report |
| Nov 1, 2023 | 8-K | Current Report |
| Aug 25, 2023 | 8-K | Current Report |
| Aug 7, 2023 | 8-K | Current Report |
| Aug 2, 2023 | 10-Q | Quarterly Report |
| Aug 2, 2023 | 8-K | Current Report |
| Jul 11, 2023 | 8-K | Current Report |
| May 24, 2023 | 8-K | Current Report |